{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:29:31Z","timestamp":1795026571483,"version":"4.10.2"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-96158-5","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T04:21:23Z","timestamp":1745900483000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Identification of pyroptosis-associated gene to predict fibrosis and reveal immune characterization in non-alcoholic fatty liver disease"],"prefix":"10.1038","volume":"15","author":[{"given":"Sha","family":"Tu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanying","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Sha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"96158_CR1","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jama.2020.2298","volume":"323","author":"AC Sheka","year":"2020","unstructured":"Sheka, A. C. et al. Nonalcoholic steatohepatitis: A review. JAMA 323, 1175\u20131183. https:\/\/doi.org\/10.1001\/jama.2020.2298 (2020).","journal-title":"JAMA"},{"key":"96158_CR2","doi-asserted-by":"publisher","first-page":"108391","DOI":"10.1016\/j.pharmthera.2023.108391","volume":"245","author":"H Chen","year":"2023","unstructured":"Chen, H. et al. PPAR-gamma signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets. Pharmacol. Ther. 245, 108391. https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108391 (2023).","journal-title":"Pharmacol. Ther."},{"key":"96158_CR3","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/hep.31150","volume":"71","author":"J Zhou","year":"2020","unstructured":"Zhou, J. et al. Epidemiological features of NAFLD from 1999 to 2018 in China. Hepatology 71, 1851\u20131864. https:\/\/doi.org\/10.1002\/hep.31150 (2020).","journal-title":"Hepatology"},{"key":"96158_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi, Z. et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 15, 11\u201320. https:\/\/doi.org\/10.1038\/nrgastro.2017.109 (2018).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"96158_CR5","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/joim.13531","volume":"292","author":"R Paternostro","year":"2022","unstructured":"Paternostro, R. & Trauner, M. Current treatment of non-alcoholic fatty liver disease. J. Intern. Med. 292, 190\u2013204. https:\/\/doi.org\/10.1111\/joim.13531 (2022).","journal-title":"J. Intern. Med."},{"key":"96158_CR6","doi-asserted-by":"publisher","unstructured":"Meroni, M., Longo, M., Rustichelli, A. & Dongiovanni, P. Nutrition and genetics in NAFLD: The perfect binomium. Int. J. Mol. Sci. 21 https:\/\/doi.org\/10.3390\/ijms21082986 (2020).","DOI":"10.3390\/ijms21082986"},{"key":"96158_CR7","doi-asserted-by":"publisher","unstructured":"Terrault, N. A., Francoz, C., Berenguer, M., Charlton, M. & Heimbach, J. L. T. Status report, current and future challenges. Clin Gastroenterol Hepatol 21, 2150\u20132166, (2023). https:\/\/doi.org\/10.1016\/j.cgh.2023.04.005 (2023).","DOI":"10.1016\/j.cgh.2023.04.005"},{"key":"96158_CR8","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/s41575-023-00759-2","volume":"20","author":"DQ Huang","year":"2023","unstructured":"Huang, D. Q. et al. Global epidemiology of cirrhosis\u2014aetiology, trends and predictions. Nat. Rev. Gastroenterol. Hepatol. 20, 388\u2013398. https:\/\/doi.org\/10.1038\/s41575-023-00759-2 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"96158_CR9","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S2468-1253(23)00066-3","volume":"8","author":"MA Tincopa","year":"2023","unstructured":"Tincopa, M. A. & Loomba, R. Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Lancet Gastroenterol. Hepatol. 8, 660\u2013670. https:\/\/doi.org\/10.1016\/S2468-1253(23)00066-3 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"96158_CR10","doi-asserted-by":"publisher","first-page":"101231","DOI":"10.1016\/j.mam.2023.101231","volume":"95","author":"M Parola","year":"2024","unstructured":"Parola, M. & Pinzani, M. Liver fibrosis in NAFLD\/NASH: From pathophysiology towards diagnostic and therapeutic strategies. Mol. Aspects Med. 95, 101231. https:\/\/doi.org\/10.1016\/j.mam.2023.101231 (2024).","journal-title":"Mol. Aspects Med."},{"key":"96158_CR11","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1002\/hep.30946","volume":"70","author":"R Loomba","year":"2019","unstructured":"Loomba, R. & Adams, L. A. The 20% rule of NASH progression: The natural history of advanced fibrosis and cirrhosis caused by NASH. Hepatology 70, 1885\u20131888. https:\/\/doi.org\/10.1002\/hep.30946 (2019).","journal-title":"Hepatology"},{"key":"96158_CR12","doi-asserted-by":"publisher","first-page":"e30387","DOI":"10.1016\/j.heliyon.2024.e30387","volume":"10","author":"AM Samy","year":"2024","unstructured":"Samy, A. M., Kandeil, M. A., Sabry, D., Abdel-Ghany, A. A. & Mahmoud, M. O. From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences. Heliyon 10, e30387. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e30387 (2024).","journal-title":"Heliyon"},{"key":"96158_CR13","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1111\/j.1572-0241.1999.01377.x","volume":"94","author":"EM Brunt","year":"1999","unstructured":"Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A. & Bacon, B. R. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 94, 2467\u20132474. https:\/\/doi.org\/10.1111\/j.1572-0241.1999.01377.x (1999).","journal-title":"Am. J. Gastroenterol."},{"key":"96158_CR14","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American association for the study of liver diseases. Hepatology 67, 328\u2013357. https:\/\/doi.org\/10.1002\/hep.29367 (2018).","journal-title":"Hepatology"},{"key":"96158_CR15","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.jhep.2023.03.038","volume":"79","author":"F Tacke","year":"2023","unstructured":"Tacke, F., Puengel, T., Loomba, R. & Friedman, S. L. An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH. J. Hepatol. 79, 552\u2013566. https:\/\/doi.org\/10.1016\/j.jhep.2023.03.038 (2023).","journal-title":"J. Hepatol."},{"key":"96158_CR16","doi-asserted-by":"publisher","first-page":"103910","DOI":"10.1016\/j.drudis.2024.103910","volume":"29","author":"S Wei","year":"2024","unstructured":"Wei, S., Wang, L., Evans, P. C. & Xu, S. NAFLD and NASH: Etiology, targets and emerging therapies. Drug Discov. Today. 29, 103910. https:\/\/doi.org\/10.1016\/j.drudis.2024.103910 (2024).","journal-title":"Drug Discov Today"},{"key":"96158_CR17","doi-asserted-by":"publisher","first-page":"121185","DOI":"10.1016\/j.lfs.2022.121185","volume":"312","author":"R Khairnar","year":"2023","unstructured":"Khairnar, R., Islam, M. A., Fleishman, J. & Kumar, S. Shedding light on non-alcoholic fatty liver disease: Pathogenesis, molecular mechanisms, models, and emerging therapeutics. Life Sci. 312, 121185. https:\/\/doi.org\/10.1016\/j.lfs.2022.121185 (2023).","journal-title":"Life Sci."},{"key":"96158_CR18","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41577-021-00639-3","volume":"22","author":"T Huby","year":"2022","unstructured":"Huby, T. & Gautier, E. L. Immune cell-mediated features of non-alcoholic steatohepatitis. Nat. Rev. Immunol. 22, 429\u2013443. https:\/\/doi.org\/10.1038\/s41577-021-00639-3 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"96158_CR19","doi-asserted-by":"publisher","first-page":"106489","DOI":"10.1016\/j.intimp.2020.106489","volume":"84","author":"A Al Mamun","year":"2020","unstructured":"Al Mamun, A. et al. Role of pyroptosis in liver diseases. Int. Immunopharmacol. 84, 106489. https:\/\/doi.org\/10.1016\/j.intimp.2020.106489 (2020).","journal-title":"Int. Immunopharmacol."},{"key":"96158_CR20","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41575-023-00807-x","volume":"20","author":"L Hammerich","year":"2023","unstructured":"Hammerich, L. & Tacke, F. Hepatic inflammatory responses in liver fibrosis. Nat. Rev. Gastroenterol. Hepatol. 20, 633\u2013646. https:\/\/doi.org\/10.1038\/s41575-023-00807-x (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"96158_CR21","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1158\/2159-8290.CD-19-0672","volume":"10","author":"DA Erkes","year":"2020","unstructured":"Erkes, D. A. et al. Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis. Cancer Discov. 10, 254\u2013269. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0672 (2020).","journal-title":"Cancer Discov"},{"key":"96158_CR22","doi-asserted-by":"publisher","first-page":"4310","DOI":"10.7150\/thno.71086","volume":"12","author":"Z Rao","year":"2022","unstructured":"Rao, Z. et al. Pyroptosis in inflammatory diseases and cancer. Theranostics 12, 4310\u20134329. https:\/\/doi.org\/10.7150\/thno.71086 (2022).","journal-title":"Theranostics"},{"key":"96158_CR23","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41392-021-00507-5","volume":"6","author":"P Yu","year":"2021","unstructured":"Yu, P. et al. Pyroptosis: Mechanisms and diseases. Signal. Transduct. Target. Ther. 6, 128. https:\/\/doi.org\/10.1038\/s41392-021-00507-5 (2021).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"96158_CR24","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jhep.2020.07.041","volume":"74","author":"S Gaul","year":"2021","unstructured":"Gaul, S. et al. Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis. J. Hepatol. 74, 156\u2013167. https:\/\/doi.org\/10.1016\/j.jhep.2020.07.041 (2021).","journal-title":"J. Hepatol."},{"key":"96158_CR25","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.jhep.2017.11.040","volume":"68","author":"B Xu","year":"2018","unstructured":"Xu, B. et al. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice. J. Hepatol. 68, 773\u2013782. https:\/\/doi.org\/10.1016\/j.jhep.2017.11.040 (2018).","journal-title":"J. Hepatol."},{"key":"96158_CR26","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/bioinformatics\/bts034","volume":"28","author":"JT Leek","year":"2012","unstructured":"Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The Sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28, 882\u2013883. https:\/\/doi.org\/10.1093\/bioinformatics\/bts034 (2012).","journal-title":"Bioinformatics"},{"key":"96158_CR27","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550. https:\/\/doi.org\/10.1186\/s13059-014-0550-8 (2014).","journal-title":"Genome Biol."},{"key":"96158_CR28","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L. G., Han, Y. & He, Q. Y. ClusterProfiler: An R package for comparing biological themes among gene clusters. OMICS 16, 284\u2013287. https:\/\/doi.org\/10.1089\/omi.2011.0118 (2012).","journal-title":"OMICS"},{"key":"96158_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330. https:\/\/doi.org\/10.1093\/nar\/28.1.27 (2000).","journal-title":"Nucleic Acids Res."},{"key":"96158_CR30","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/s0168-9525(97)01223-7","volume":"13","author":"M Kanehisa","year":"1997","unstructured":"Kanehisa, M. A database for post-genome analysis. Trends Genet. 13, 375\u2013376. https:\/\/doi.org\/10.1016\/s0168-9525(97)01223-7 (1997).","journal-title":"Trends Genet."},{"key":"96158_CR31","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon, P. et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498\u20132504. https:\/\/doi.org\/10.1101\/gr.1239303 (2003).","journal-title":"Genome Res."},{"key":"96158_CR32","doi-asserted-by":"publisher","unstructured":"Chin, C. H. et al. CytoHubba: Identifying hub objects and sub-networks from complex interactome. BMC Syst. Biol. 8 (Suppl 4). https:\/\/doi.org\/10.1186\/1752-0509-8-S4-S11 (2014).","DOI":"10.1186\/1752-0509-8-S4-S11"},{"key":"96158_CR33","doi-asserted-by":"publisher","unstructured":"Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: Gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 14 https:\/\/doi.org\/10.1186\/1471-2105-14-7 (2013).","DOI":"10.1186\/1471-2105-14-7"},{"key":"96158_CR34","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara, K. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 4, 2612. https:\/\/doi.org\/10.1038\/ncomms3612 (2013).","journal-title":"Nat. Commun."},{"key":"96158_CR35","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41568-019-0123-y","volume":"19","author":"R Karki","year":"2019","unstructured":"Karki, R. & Kanneganti, T. D. Diverging inflammasome signals in tumorigenesis and potential targeting. Nat. Rev. Cancer. 19, 197\u2013214. https:\/\/doi.org\/10.1038\/s41568-019-0123-y (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"96158_CR36","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.21037\/tlcr-21-715","volume":"10","author":"X Wang","year":"2021","unstructured":"Wang, X. et al. Cross-talk of pyroptosis and tumor immune landscape in lung adenocarcinoma. Transl Lung Cancer Res. 10, 4423\u20134444. https:\/\/doi.org\/10.21037\/tlcr-21-715 (2021).","journal-title":"Transl Lung Cancer Res."},{"key":"96158_CR37","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1146\/annurev-immunol-073119-095439","volume":"38","author":"S Kesavardhana","year":"2020","unstructured":"Kesavardhana, S., Malireddi, R. K. S. & Kanneganti, T. D. Caspases in cell death, inflammation, and pyroptosis. Annu. Rev. Immunol. 38, 567\u2013595. https:\/\/doi.org\/10.1146\/annurev-immunol-073119-095439 (2020).","journal-title":"Annu. Rev. Immunol."},{"key":"96158_CR38","doi-asserted-by":"publisher","first-page":"e21497","DOI":"10.1096\/fj.202002402R","volume":"35","author":"S Tu","year":"2021","unstructured":"Tu, S. et al. Fluorofenidone protects liver against inflammation and fibrosis by blocking the activation of NF-kappaB pathway. FASEB J. 35, e21497. https:\/\/doi.org\/10.1096\/fj.202002402R (2021).","journal-title":"FASEB J."},{"key":"96158_CR39","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell, E. E., Wong, V. W. & Rinella, M. Non-alcoholic fatty liver disease. Lancet 397, 2212\u20132224. https:\/\/doi.org\/10.1016\/S0140-6736(20)32511-3 (2021).","journal-title":"Lancet"},{"key":"96158_CR40","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi, K. et al. The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 7, 851\u2013861. https:\/\/doi.org\/10.1016\/S2468-1253(22)00165-0 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"96158_CR41","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/hep.32542","volume":"77","author":"PA Shah","year":"2023","unstructured":"Shah, P. A., Patil, R. & Harrison, S. A. NAFLD-related hepatocellular carcinoma: The growing challenge. Hepatology 77, 323\u2013338. https:\/\/doi.org\/10.1002\/hep.32542 (2023).","journal-title":"Hepatology"},{"key":"96158_CR42","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41575-023-00754-7","volume":"20","author":"JM Llovet","year":"2023","unstructured":"Llovet, J. M. et al. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: Pathogenesis and treatment. Nat. Rev. Gastroenterol. Hepatol. 20, 487\u2013503. https:\/\/doi.org\/10.1038\/s41575-023-00754-7 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"96158_CR43","doi-asserted-by":"publisher","first-page":"106139","DOI":"10.1016\/j.phrs.2022.106139","volume":"178","author":"G Tong","year":"2022","unstructured":"Tong, G. et al. Fibroblast growth factor 18 attenuates liver fibrosis and HSCs activation via the SMO-LATS1-YAP pathway. Pharmacol. Res. 178, 106139. https:\/\/doi.org\/10.1016\/j.phrs.2022.106139 (2022).","journal-title":"Pharmacol. Res."},{"key":"96158_CR44","doi-asserted-by":"publisher","first-page":"e13158","DOI":"10.1111\/cpr.13158","volume":"55","author":"S Yuan","year":"2022","unstructured":"Yuan, S. et al. Sorafenib attenuates liver fibrosis by triggering hepatic stellate cell ferroptosis via HIF-1alpha\/SLC7A11 pathway. Cell. Prolif. 55, e13158. https:\/\/doi.org\/10.1111\/cpr.13158 (2022).","journal-title":"Cell. Prolif."},{"key":"96158_CR45","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.3389\/fimmu.2020.01802","volume":"11","author":"X Pan","year":"2020","unstructured":"Pan, X. et al. Chemokines in Non-alcoholic fatty liver disease: A systematic review and network meta-analysis. Front. Immunol. 11, 1802. https:\/\/doi.org\/10.3389\/fimmu.2020.01802 (2020).","journal-title":"Front. Immunol."},{"key":"96158_CR46","doi-asserted-by":"publisher","unstructured":"Kang, J. et al. Notch-mediated hepatocyte MCP-1 secretion causes liver fibrosis. JCI Insight. 8 https:\/\/doi.org\/10.1172\/jci.insight.165369 (2023).","DOI":"10.1172\/jci.insight.165369"},{"key":"96158_CR47","doi-asserted-by":"publisher","first-page":"e0260313","DOI":"10.1371\/journal.pone.0260313","volume":"16","author":"A Goyale","year":"2021","unstructured":"Goyale, A. et al. Assessment of non-alcoholic fatty liver disease (NAFLD) severity with novel serum-based markers: A pilot study. PLoS ONE. 16, e0260313. https:\/\/doi.org\/10.1371\/journal.pone.0260313 (2021).","journal-title":"PLoS One"},{"key":"96158_CR48","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41575-019-0210-2","volume":"17","author":"S Sutti","year":"2020","unstructured":"Sutti, S. & Albano, E. Adaptive immunity: An emerging player in the progression of NAFLD. Nat. Rev. Gastroenterol. Hepatol. 17, 81\u201392. https:\/\/doi.org\/10.1038\/s41575-019-0210-2 (2020).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"96158_CR49","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/hep.31755","volume":"74","author":"F Barrow","year":"2021","unstructured":"Barrow, F. et al. Microbiota-driven activation of intrahepatic B cells aggravates NASH through innate and adaptive signaling. Hepatology 74, 704\u2013722. https:\/\/doi.org\/10.1002\/hep.31755 (2021).","journal-title":"Hepatology"},{"key":"96158_CR50","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","volume":"15","author":"S Schuster","year":"2018","unstructured":"Schuster, S., Cabrera, D., Arrese, M. & Feldstein, A. E. Triggering and resolution of inflammation in NASH. Nat. Rev. Gastroenterol. Hepatol. 15, 349\u2013364. https:\/\/doi.org\/10.1038\/s41575-018-0009-6 (2018).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"96158_CR51","doi-asserted-by":"publisher","first-page":"1098056","DOI":"10.3389\/fimmu.2023.1098056","volume":"14","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. Characteristic gene expression in the liver monocyte-macrophage-DC system is associated with the progression of fibrosis in NASH. Front. Immunol. 14, 1098056. https:\/\/doi.org\/10.3389\/fimmu.2023.1098056 (2023).","journal-title":"Front. Immunol."},{"key":"96158_CR52","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/hep.26267","volume":"58","author":"JR Henning","year":"2013","unstructured":"Henning, J. R. et al. Dendritic cells limit fibroinflammatory injury in nonalcoholic steatohepatitis in mice. Hepatology 58, 589\u2013602. https:\/\/doi.org\/10.1002\/hep.26267 (2013).","journal-title":"Hepatology"},{"key":"96158_CR53","doi-asserted-by":"publisher","first-page":"108626","DOI":"10.1016\/j.celrep.2020.108626","volume":"34","author":"S Daemen","year":"2021","unstructured":"Daemen, S. et al. Dynamic shifts in the composition of resident and recruited macrophages influence tissue remodeling in NASH. Cell. Rep. 34, 108626. https:\/\/doi.org\/10.1016\/j.celrep.2020.108626 (2021).","journal-title":"Cell. Rep."},{"key":"96158_CR54","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/hep.31713","volume":"74","author":"L Kennedy","year":"2021","unstructured":"Kennedy, L. et al. Mast cells promote nonalcoholic fatty liver disease phenotypes and microvesicular steatosis in mice fed a Western diet. Hepatology 74, 164\u2013182. https:\/\/doi.org\/10.1002\/hep.31713 (2021).","journal-title":"Hepatology"},{"key":"96158_CR55","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.humpath.2018.11.029","volume":"86","author":"J Lombardo","year":"2019","unstructured":"Lombardo, J. et al. Hepatic mast cell concentration directly correlates to stage of fibrosis in NASH. Hum. Pathol. 86, 129\u2013135. https:\/\/doi.org\/10.1016\/j.humpath.2018.11.029 (2019).","journal-title":"Hum. Pathol."},{"key":"96158_CR56","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41423-021-00832-3","volume":"19","author":"A Herrero-Cervera","year":"2022","unstructured":"Herrero-Cervera, A., Soehnlein, O. & Kenne, E. Neutrophils in chronic inflammatory diseases. Cell. Mol. Immunol. 19, 177\u2013191. https:\/\/doi.org\/10.1038\/s41423-021-00832-3 (2022).","journal-title":"Cell. Mol. Immunol."},{"key":"96158_CR57","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1136\/gutjnl-2020-322509","volume":"70","author":"EH Koh","year":"2021","unstructured":"Koh, E. H. et al. Sphingomyelin synthase 1 mediates hepatocyte pyroptosis to trigger non-alcoholic steatohepatitis. Gut 70, 1954\u20131964. https:\/\/doi.org\/10.1136\/gutjnl-2020-322509 (2021).","journal-title":"Gut"},{"key":"96158_CR58","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41419-024-07151-1","volume":"15","author":"R Zhao","year":"2024","unstructured":"Zhao, R. et al. Hepatocyte-specific NR5A2 deficiency induces pyroptosis and exacerbates non-alcoholic steatohepatitis by downregulating ALDH1B1 expression. Cell. Death Dis. 15, 770. https:\/\/doi.org\/10.1038\/s41419-024-07151-1 (2024).","journal-title":"Cell. Death Dis."},{"key":"96158_CR59","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","volume":"66","author":"AR Mridha","year":"2017","unstructured":"Mridha, A. R. et al. NLRP3 inflammasome Blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J. Hepatol. 66, 1037\u20131046. https:\/\/doi.org\/10.1016\/j.jhep.2017.01.022 (2017).","journal-title":"J. Hepatol."},{"key":"96158_CR60","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ajpath.2019.09.011","volume":"190","author":"J Qi","year":"2020","unstructured":"Qi, J., Kim, J. W., Zhou, Z., Lim, C. W. & Kim, B. Ferroptosis affects the progression of nonalcoholic steatohepatitis via the modulation of lipid Peroxidation-Mediated cell death in mice. Am. J. Pathol. 190, 68\u201381. https:\/\/doi.org\/10.1016\/j.ajpath.2019.09.011 (2020).","journal-title":"Am. J. Pathol."},{"key":"96158_CR61","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/hep.29495","volume":"67","author":"A Wree","year":"2018","unstructured":"Wree, A., Inzaugarat, M. E. & Feldstein, A. E. Transmembrane BAX inhibitor motif-containing 1, a novel anti-inflammatory approach for nonalcoholic steatohepatitis treatment. Hepatology 67, 438\u2013441. https:\/\/doi.org\/10.1002\/hep.29495 (2018).","journal-title":"Hepatology"},{"key":"96158_CR62","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.bbrc.2023.08.067","volume":"679","author":"X Chen","year":"2023","unstructured":"Chen, X., Wang, D., Wang, Z. & Huang, W. Identification of pyroptosis-related genes in NASH based on bioinformatic analysis. Biochem. Biophys. Res. Commun. 679, 90\u201397. https:\/\/doi.org\/10.1016\/j.bbrc.2023.08.067 (2023).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"96158_CR63","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1038\/s41598-024-53599-8","volume":"14","author":"F Mao","year":"2024","unstructured":"Mao, F. et al. Identification of pyroptosis-related gene signature in nonalcoholic steatohepatitis. Sci. Rep. 14, 3175. https:\/\/doi.org\/10.1038\/s41598-024-53599-8 (2024).","journal-title":"Sci. Rep."},{"key":"96158_CR64","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.tips.2021.11.001","volume":"43","author":"AZ Spitz","year":"2022","unstructured":"Spitz, A. Z. & Gavathiotis, E. Physiological and pharmacological modulation of BAX. Trends Pharmacol. Sci. 43, 206\u2013220. https:\/\/doi.org\/10.1016\/j.tips.2021.11.001 (2022).","journal-title":"Trends Pharmacol. Sci."},{"key":"96158_CR65","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1038\/s41467-024-46785-9","volume":"15","author":"Y Jiang","year":"2024","unstructured":"Jiang, Y. et al. Reciprocal Inhibition between TP63 and STAT1 regulates anti-tumor immune response through interferon-gamma signaling in squamous cancer. Nat. Commun. 15, 2484. https:\/\/doi.org\/10.1038\/s41467-024-46785-9 (2024).","journal-title":"Nat. Commun."},{"key":"96158_CR66","doi-asserted-by":"publisher","unstructured":"Moses, M. A. et al. Molecular mechanisms of p63-Mediated squamous cancer pathogenesis. Int. J. Mol. Sci. 20 https:\/\/doi.org\/10.3390\/ijms20143590 (2019).","DOI":"10.3390\/ijms20143590"},{"key":"96158_CR67","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.gendis.2021.12.006","volume":"10","author":"HV Charan","year":"2023","unstructured":"Charan, H. V., Dwivedi, D. K., Khan, S. & Jena, G. Mechanisms of NLRP3 inflammasome-mediated hepatic stellate cell activation: Therapeutic potential for liver fibrosis. Genes Dis. 10, 480\u2013494. https:\/\/doi.org\/10.1016\/j.gendis.2021.12.006 (2023).","journal-title":"Genes Dis."},{"key":"96158_CR68","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1136\/gutjnl-2020-322526","volume":"70","author":"X Wang","year":"2021","unstructured":"Wang, X., He, Y., Mackowiak, B. & Gao, B. MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases. Gut 70, 784\u2013795. https:\/\/doi.org\/10.1136\/gutjnl-2020-322526 (2021).","journal-title":"Gut"},{"key":"96158_CR69","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrgastro.2017.71","volume":"14","author":"G Szabo","year":"2017","unstructured":"Szabo, G. & Momen-Heravi, F. Extracellular vesicles in liver disease and potential as biomarkers and therapeutic targets. Nat. Rev. Gastroenterol. Hepatol. 14, 455\u2013466. https:\/\/doi.org\/10.1038\/nrgastro.2017.71 (2017).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96158-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96158-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96158-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T04:21:24Z","timestamp":1745900484000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96158-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["96158"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-96158-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"assertion":[{"value":"25 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal experimental protocol is in accordance with The Institutional Animal Care and Use Committee Guangdong Provincial People\u2019s Hospital. The current study is reported in accordance with ARRIVE guidelines ().","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14944"}}